Abstract
Background: Dupilumab is a monoclonal antibody antagonist of the interleukin 4 (IL-4) receptor alpha and was approved for the treatment of moderate-to-severe atopic dermatitis in 2017. Little data exist on the national prescribing patterns of dupilumab and the goal of this study was to assess these patterns. Design: A retrospective analysis was conducted using the Medicare Part D Prescriber datasets from 2017-2019. Data from dupilumab prescriptions made by any type of healthcare provider were analyzed. Yearly claims per 100,000 beneficiaries, total drug costs, and total drug supply days were recorded. Average annual growth rate (AAGR) was calculated. Summary: From 2017-2019, the number of dupilumab prescribers who made ≥11 claims to Medicare Part D enrollees increased by 416%. The majority of the prescribers were dermatologists, followed by advanced practice providers and allergists. The highest proportion of claims and beneficiaries receiving dupilumab each year were those >65 years of age and located in the South. AAGR increased for yearly claims per 100,000 beneficiaries (AAGR = 200%), total drug costs (AAGR = 216%), and total drug supply days (AAGR = 396%). Conclusion: The prescribing trends of dupilumab continues to grow significantly across all providers in claims made per 100k beneficiaries, total drug costs, and total drug supply days. These findings demonstrate the increasing access to dupilumab, and as other indications receive approval, additional studies will be needed to assess whether this trajectory continues.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
